SwishX Launches Agentic AI Platform for Pharma & Medtech, Raises $2.2 Mn Seed Funding

The company said it plans to expand into emerging markets including Latin America, Southeast Asia, the Middle East, Africa, and Eastern Europe.

SwishX has launched what it describes as an Agentic AI platform built specifically for pharmaceutical and medtech companies, alongside announcing $2.2 million in seed funding from investors including Powerhouse Ventures, Blume Ventures, Sadev Ventures, and Atrium Ventures.

Founded by former Google and Amazon executives Dushyant Sapre and Jai Anand, the Bengaluru-based startup is targeting $5 million in contracted annual recurring revenue (ARR) and over 100 enterprise clients by the end of FY 2026–27.

The company said it plans to expand into emerging markets including Latin America, Southeast Asia, the Middle East, Africa, and Eastern Europe.

SwishX’s platform is designed to automate commercial operations for pharma and medtech companies through AI agents capable of analyzing data, automating workflows, and supporting business decision-making. The platform focuses on areas such as sales, marketing, distribution, and government tender management.

According to the company, pharmaceutical firms continue to rely heavily on spreadsheets, disconnected software systems, manual workflows, and delayed reporting for key commercial decisions. SwishX said its AI-led platform aims to address these inefficiencies and improve revenue outcomes by up to 30%.

The platform can autonomously analyze thousands of public tenders, identify high-probability opportunities, process lengthy procurement documents, recommend pricing strategies, and draft proposals. SwishX also said the system can convert marketing documents into personalized video content for doctors within a day.

The company is initially focused on India but said it is integrating local market intelligence from multiple countries to support international operations.

SwishX stated that the platform has been built specifically for emerging markets, where pharmaceutical supply chains and procurement structures are more fragmented and complex. India alone has more than 1.2 million pharmacies, while a significant share of procurement is conducted through government tenders and rate contracts.

The startup enters the market as pharmaceutical companies accelerate AI adoption globally. Industry estimates cited by the company suggest AI could generate between $60 billion and $110 billion in annual value for the sector.

SwishX said its long-term roadmap includes expanding beyond commercial operations into AI-driven drug discovery, biosimilar development, and autonomous multi-market execution systems for life sciences companies.

Stay tuned for more such updates on Digital Health News